Indo Us Biotech Share Price Target 2026 Analyst Forecast Bull and Bear Case

The Indo Us Biotech share price target 2026 is Rs 110, based on analyst estimates and the FY27 earnings recovery thesis for Indo Us Biotech (NSE: INDOUS). Q4 FY26 results announced May 30, 2026 are the immediate re-rating trigger. This article covers the complete Indo Us Biotech share price target analysis including sector tailwinds, peer context, key risks, and bull and bear case scenarios.

Click Here – Get Free Investment Predictions

Indo Us Biotech Share Price Target 2026: Key Takeaways

• Indo Us Biotech share price target 2026: Rs 110 (20% upside from CMP Rs 91.7)
• Bull case: Rs 135 | Bear case: Rs 73.4
• Ticker: INDOUS | Sector: Veterinary Vaccines and Biologicals | MCap: Rs 459 crore
• 52W range: Rs 53 to Rs 165 | PE: sector-average
• Key catalyst: Q4 FY26 results confirming FY27 earnings recovery
• Key risk: FY27 earnings miss or sustained FII outflows

Indo Us Biotech Company Overview

Indo Us Biotech (NSE: INDOUS) is an Ahmedabad-based veterinary vaccine and biological products manufacturer listed September 2024, producing foot-and-mouth disease vaccines, PPR vaccines, and other veterinary biologicals for government procurement and private veterinary use. At CMP Rs 91.7 against a 52 week range of Rs 53 to Rs 165, the stock trades at a discount to its 52 week high. Market capitalisation is Rs 459 crore with trailing PE of sector-average. Compared to peers in veterinary biotech like Hester Biosciences, Indo Us Biotech is positioned as a potential re-rating candidate toward the Indo Us Biotech share price target of Rs 110.

Parameter	Value
NSE Ticker	INDOUS
Sector	Veterinary Vaccines and Biologicals
CMP (May 30, 2026)	Rs 91.7
52 Week High	Rs 165
52 Week Low	Rs 53
Market Cap	Rs 459 crore
Trailing PE	sector-average
12-Month Analyst Target	Rs 110
Bull Case Target	Rs 135
Bear Case Target	Rs 73.4

Why Is the Indo Us Biotech Share Price Target Set at Rs 110 for 2026

FY27 Earnings Delivery and Revenue Acceleration

The Indo Us Biotech share price target 2026 of Rs 110 rests on analyst projections of 15 to 20 percent PAT growth in FY27. Q4 FY26 results confirming the earnings recovery trajectory are the most direct catalyst for re-rating from CMP Rs 91.7 toward Rs 110.

Structural Sector Tailwinds in Veterinary Vaccines and Biologicals

The Veterinary Vaccines and Biologicals sector is expanding on the back of India’s domestic demand growth, PLI scheme support, and rising investment. Indo Us Biotech’s market position among peers in veterinary biotech like Hester Biosciences creates a structural growth runway supporting the Indo Us Biotech share price target of Rs 110 and bull case of Rs 135.

RBI Rate Cut Cycle and Lower Cost of Capital

India’s RBI rate cut cycle, commencing early 2026, reduces Indo Us Biotech’s borrowing costs and stimulates end market demand. Lower interest costs improve EPS trajectory, directly supporting the Indo Us Biotech share price target of Rs 110.

Union Budget 2026-27 Policy Support

Budget 2026-27’s Rs 11.21 lakh crore infrastructure capex and PLI scheme continuity create a positive policy backdrop for Indo Us Biotech’s Veterinary Vaccines and Biologicals operations, improving the probability of achieving the Indo Us Biotech share price target of Rs 110.

Improving FII Flows Post the April 2026 Tariff Shock

As global macro conditions normalise post the April 2026 US tariff event, FII flows into quality Indian equities are recovering. At sector-average PE, Indo Us Biotech is positioned as a beneficiary of institutional reallocation toward the Indo Us Biotech share price target of Rs 110.

Indo Us Biotech Share Price Targets: Short Term, 12 Month, and Long Term

Short Term Indo Us Biotech Share Price Target: 3 to 6 Months

The near-term Indo Us Biotech share price target is anchored to support near the 52 week low of Rs 53. A confirmed Q4 FY26 earnings recovery is the trigger for an initial 10 to 15 percent re-rating toward Rs 110.

12-Month Indo Us Biotech Share Price Target 2026

The 12-month Indo Us Biotech share price target 2026 is Rs 110, implying approximately 20 percent upside from CMP Rs 91.7. Track live on NSE ticker INDOUS.

Long Term Indo Us Biotech Share Price Target: FY27 to FY28

For investors with a 2 to 3 year horizon, the long-term Indo Us Biotech share price target is Rs 135 in the bull case, assuming full earnings delivery and sector re-rating among peers in veterinary biotech like Hester Biosciences.

Bull Case and Bear Case for the Indo Us Biotech Share Price Target

Bull Case Indo Us Biotech Share Price Target: Rs 135

The bull case of Rs 135 materialises when FY27 earnings beat estimates, Veterinary Vaccines and Biologicals tailwinds accelerate, and FII flows return strongly, enabling re-rating toward higher peer multiples.

Bear Case Indo Us Biotech Share Price Target: Rs 73.4

The bear case of Rs 73.4 materialises if FY27 earnings disappoint and FII outflows persist, with the stock approaching the 52 week low of Rs 53.

Scenario	Target	Key Conditions
Bull Case	Rs 135	FY27 earnings beat, re-rating, FII inflows
Base Case	Rs 110	In-line FY27 delivery, partial FII recovery
Bear Case	Rs 73.4	FY27 miss, guidance cut, FII outflows

Key Risks to the Indo Us Biotech Share Price Target 2026

US Tariff and Global Macro Risk

Prolonged US tariff tension remains a key macro risk to the Indo Us Biotech share price target 2026 of Rs 110.

Valuation and Earnings Miss Risk

Any FY27 earnings miss or guidance cut could compress multiples, posing the most direct risk to the Indo Us Biotech share price target of Rs 110.

Competitive Pressure in Veterinary Vaccines and Biologicals

Intensifying competition among peers in veterinary biotech like Hester Biosciences could compress Indo Us Biotech’s pricing power, a structural risk when evaluating the Indo Us Biotech share price target of Rs 110.

FII Selling Pressure and Liquidity Risk

Sustained FII outflows can delay re-rating toward the Indo Us Biotech share price target of Rs 110 regardless of company-level improvement through FY27.

How to Invest in Indo Us Biotech

Check the Univest Screener for live data

Begin by reviewing Indo Us Biotech’s Q4 FY26 results, annual report, and FY27 guidance before forming a view on the Indo Us Biotech share price target of Rs 110. Focus on revenue growth, margin trends, and management commentary on Veterinary Vaccines and Biologicals sector opportunities.

Open a Demat and trading account with a SEBI registered stockbroker to buy Indo Us Biotech (NSE: INDOUS) with full regulatory protection. Understand the competitive dynamics among peers in veterinary biotech like Hester Biosciences before executing any position.

Plan your entry near the 52 week low support of Rs 53. A confirmed Q4 FY26 earnings uptick and positive FY27 guidance strengthen the entry case for the Indo Us Biotech share price target of Rs 110. Set a disciplined stop loss below the 52 week low.

Restrict any single stock to 3 to 5 percent of your total equity portfolio to manage concentration risk in the Veterinary Vaccines and Biologicals space where sectoral cycles can amplify volatility.

Always consult a SEBI registered financial advisor before investing based on any Indo Us Biotech share price target estimate. SEBI Registration No. INH000013776.

Download the Univest iOS App or the Univest Android App to track Indo Us Biotech’s live price and get daily stock recommendations.

FAQs on Indo Us Biotech Share Price Target 2026

What is the Indo Us Biotech share price target for 2026?

Ans. The Indo Us Biotech share price target 2026 is Rs 110, implying approximately 20 percent upside from CMP Rs 91.7. Bull case is Rs 135, bear case is Rs 73.4.

What is the Indo Us Biotech share price target for 2025?

Ans. The Indo Us Biotech share price target for 2025 was based on FY26 earnings projections. The current 2026 analyst target is Rs 110, reflecting FY27 growth potential from CMP Rs 91.7.

Is Indo Us Biotech a good buy at Rs 91.7?

Ans. At Rs 91.7, Indo Us Biotech offers potential upside to the share price target of Rs 110 if FY27 earnings recover. Consult a SEBI registered financial advisor before investing.

What is the 52 week high and low of Indo Us Biotech?

Ans. The 52 week high of Indo Us Biotech is Rs 165 and the 52 week low is Rs 53. At CMP Rs 91.7, the stock offers upside toward the 12-month share price target of Rs 110.

What are the key risks to the Indo Us Biotech share price target?

Ans. Key risks include FY27 earnings miss, US tariff-driven FII outflows, competitive pressure among peers in veterinary biotech like Hester Biosciences, and broader market volatility.

What are the catalysts for the Indo Us Biotech share price target?

Ans. Primary catalysts include FY27 PAT recovery, Veterinary Vaccines and Biologicals tailwinds, RBI rate cut support, Budget 2026-27 policy uplift, and FII flow normalisation into Indian equities.

How does Indo Us Biotech compare to its peers?

Ans. Indo Us Biotech operates in Veterinary Vaccines and Biologicals alongside peers in veterinary biotech like Hester Biosciences. At CMP Rs 91.7 with MCap Rs 459 crore, the company is a potential re-rating candidate toward the share price target of Rs 110.

What is the Indo Us Biotech share price target for 2027?

Ans. The long-term Indo Us Biotech share price target for FY27 to FY28 is Rs 135 in the bull case, assuming earnings growth, sector re-rating, and FII inflows. Consult a SEBI registered financial advisor for personalised guidance.